Latanoprost+timolol-Uk (Timolol Maleate, Latanoprost)

Latanoprost, a prostaglandin F (FP) receptor agonist, increases uveoscleral outflow of aqueous humor, facilitating drainage from the eye. Timolol maleate, a non‑selective beta‑adrenergic blocker, reduces aqueous humor production by inhibiting β‑receptors in the ciliary body. Together they provide a dual mechanism that more effectively lowers intra‑ocular pressure than either agent alone.

The dosing regimen is determined by the prescribing clinician. Typically, one drop is instilled into each affected eye once daily, but the exact dose, frequency, and duration are individualized based on the patient’s response and clinical judgment.

Safety data in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should discuss individual circumstances and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

When used separately, each agent lowers intra‑ocular pressure through a single pathway. The combination offers additive pressure reduction by simultaneously increasing outflow (Latanoprost) and decreasing production (Timolol), often achieving greater target‑pressure control and reducing the need for additional medications.

The ophthalmic solution should be stored at room temperature, preferably below 25 °C, in its original container. Protect it from direct light, moisture, and extreme temperatures. Keep the bottle tightly closed when not in use to maintain sterility.

The medication is applied as a sterile eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and place one drop into the conjunctival sac. Close the eye gently for a few seconds without blinking excessively, and avoid touching the tip of the bottle to any surface.

Serious adverse events include severe allergic reactions (e.g., swelling, rash, anaphylaxis), persistent ocular inflammation such as uveitis or keratitis, marked systemic bradycardia, and bronchospasm in patients with reactive airway disease. Any of these symptoms require immediate medical attention and discontinuation of the product.

Patients with known hypersensitivity to either component, severe bradycardia, advanced heart block, uncontrolled asthma, or chronic obstructive pulmonary disease should avoid this medication. It is also contraindicated in individuals using non‑selective systemic beta‑blockers when additive cardiac effects could be hazardous.